Cargando…
The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis
BACKGROUND: Calcific uraemic arteriolopathy (CUA; calciphylaxis) is a rare disease seen predominantly in patients receiving dialysis. Calciphylaxis is characterized by poorly healing or non-healing wounds, and is associated with mortality, substantial morbidity related to infection and typically sev...
Autores principales: | Sinha, Smeeta, Gould, Lisa J, Nigwekar, Sagar U, Serena, Thomas E, Brandenburg, Vincent, Moe, Sharon M, Aronoff, George, Chatoth, Dinesh K, Hymes, Jeffrey L, Miller, Stephan, Padgett, Claire, Carroll, Kevin J, Perelló, Joan, Gold, Alex, Chertow, Glenn M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757410/ https://www.ncbi.nlm.nih.gov/pubmed/35035944 http://dx.doi.org/10.1093/ckj/sfab117 |
Ejemplares similares
-
Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis — Subgroup Analyses of the CALIPSO Trial
por: Raggi, Paolo, et al.
Publicado: (2020) -
Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification
por: Bellasi, Antonio, et al.
Publicado: (2019) -
Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification
por: Ferrer, Miguel D., et al.
Publicado: (2018) -
Development of the BWAT-CUA Scale to Assess Wounds in Patients with Calciphylaxis
por: Gould, Lisa J., et al.
Publicado: (2021) -
Calciphylaxis in end-stage kidney disease: outcome data from the United Kingdom Calciphylaxis Study
por: Chinnadurai, Rajkumar, et al.
Publicado: (2021)